Amid plans to transfer manufacturing for an investigational vaccine to a souped-up plant in Pennsylvania, GSK is parting ways ...

The Cambridge site of an international biotechnology company will cease manufacturing, leaving 150 people without a job.

CEO Emma Walmsley’s 40-bln-pound 2031 sales target looks fanciful after another disappointing drug trial. A healthy balance ...

A global biopharmaceutical company headquartered in London announced the layoffs of 150 Massachusetts employees last week.

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March 2026, the company said in a notice to the state. The company said Monday ...

GSK faces an "unplanned, short-term drop in Rotarix production for 2022," thanks to unspecified "manufacturing challenges," the company told Fierce.

- Adaptimmune plans to be IND-ready in 2023 with a PRAME targeted TCR T-cell therapy - - Adaptimmune and GSK will work collaboratively to ensure continuity for patients in ongoing clinical trials ...

We recently published a list of Domestic Manufacturing Boom: 12 Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where GSK plc (NYSE:GSK) stands against other ...